Inactivation of key pathway boosts the body’s immune response against tumors

Targeting CDK12/13 improves the efficiency of cancer therapies

5:00 AM

Author | Ananya Sen

close up of microscope image lighter blue up top looks to be glowing and lower not glowing and more black
Tumor cells lacking CDK12, top, have higher STING activity compared to the control. Credit: Arul Chinnaiyan

Immunotherapy uses the body’s immune system to recognize and destroy cancer cells.

One way to do this is through immune checkpoint inhibitors.

Immune checkpoints are a normal part of the immune system, and they help prevent the immune response from destroying healthy cells in the body.

Therapeutic drugs that set up an immune checkpoint blockade inhibit proteins that prevent the immune system from attacking cancer cells.

As a result, T cells can more effectively target and destroy tumors.

However, many patients are resistant to this therapy, which poses a challenge to their treatment.

A study led by researchers from the University of Michigan showed that targeting CDK12 and a related gene, CDK13, strongly activates the stimulator of interferon genes, or STING, signaling pathway, enhancing the effectiveness of immunotherapies.

The work was published in The Journal of Clinical Investigation.

Previously, U-M researchers had identified a new subtype of aggressive prostate cancer and had shown that patients who have lost the CDK12 gene develop metastatic disease.

This finding prompted them to further investigate the role of CDK12.

Using preclinical models, they later found that targeting CDK12/13 results in STING activation.

In this process, CDK12 loss activates other genes that drive cancer.

Both the overexpression of these genes as they try to create proteins and the rapid DNA replication causes a collision, resulting in DNA damage.

In their previous study, the team found that the inactivation of CDK12/13 was associated with higher levels of T cells in advanced prostate cancer.

To understand the connection between the immune system and CDK12/13, the team looked at metastatic prostate cancer samples with either active or inactive CDK12 in the study.

In clinical samples across a broad range of cancer types, they found that inactivation of both CDK12 and CDK13 was associated with higher STING activity and more favorable immunotherapy treatment outcomes.

The researchers confirmed these findings in preclinical models using a CDK12/13 degrader. Mice treated with this molecule had higher STING activity.

This increased activity was due to the release of DNA fragments inside tumor cells, which is a result of DNA damage triggered by the loss of CDK12/13.

STING activation, in turn, recruited T cells to the tumor, and strongly sensitized them to immune checkpoint blockade, revealing a promising novel strategy to improve current cancer therapies.

“Now the question is whether we will see similar results in clinical trials,” said Arul Chinnaiyan, M.D., Ph.D., S.P. Hicks Professor of Pathology and member of the Rogel Cancer Center.

“We hope that the CDK12/13 degraders will combine nicely with the immune checkpoint inhibitors in future therapies.”

Additional authors: Yi Bao, Yu Chang, Jean Ching-Yi Tien, Gabriel Cruz, Fan Yang, Rahul Mannan, Somnath Mahapatra, Radha Paturu, Xuhong Cao, Fengyun Su, Rui Wang, Yuping Zhang, Mahnoor Gondal, Jae Eun Choi, Jonathan K. Gurkan, Stephanie J. Miner, Dan R. Robinson, Yi-Mi Wu, Licheng Zhou, Zhen Wang, Ilona Kryczek, Xiaoju Wang, Marcin Cieslik, Yuanyuan Qiao, Alexander Tsodikov, Weiping Zou and Ke Ding.

Funding/disclosures: This research was funded by the National Cancer Institute Outstanding Investigator Award (R35CA231996), the NCI Prostate SPORE grant (P50CA186786), the NCI EDRN (U2C CA271854) and the Strategic Priority Research Program of the Chinese Academy of Sciences (Grant No. XDB1060000).

Tech transfer(s)/Conflict(s) of interest: Chinnaiyan is a co-founder and serves on the Scientific Advisory Board of Lynx Dx, Esanik Therapeutics, Medsyn and Flamingo Therapeutics. Chinnaiyan is a scientific consultant for EdenRoc, Proteovant, Aurigene Oncology, RAPPTA, Belharra and Tempus. Ding provides advisory services to Kinoteck Therapeutics and has received financial support from Livzon Pharmaceutical Group. Zou acts as a scientific advisor for NGM, CrownBio, Cstone, Proteovant, Hengenix, NextCure, and Intergalactic. Patents related to the CDK12/13 degrader, YJ1206, have been filed by both the University of Michigan and the Shanghai Institute of Organic Chemistry, with Chinnaiyan, Ding, Chang, Wang and Tien recognized as co-inventors.

Paper cited: “CDK12/13 inactivation triggers STING-mediated anti-tumor immunity in pre-clinical models,” The Journal of Clinical Investigation.  DOI: 10.1172/JCI193745

Sign up for Health Lab newsletters today. Get medical tips from top experts and learn about new scientific discoveries every week.

Sign up for the Health Lab Podcast. Add us wherever you listen to your favorite shows.  


More Articles About:

All Research Topics Cancer (Oncology) Rogel Cancer Center Urology immunotherapy
Health Lab word mark overlaying blue cells

Health Lab

Explore thousands of health news & research stories by visiting the Health Lab homepage for more.

Media Contact

University Hospital at U-M Health in the spring with flowering trees in foreground and Survival Flight helicopter visible

Public Relations

Department of Communication at Michigan Medicine

[email protected]

734-764-2220

In This Story

Arul Chinnaiyan, MD, PhD

Arul Chinnaiyan, MD, PhD

Professor

Related

Sewing Machine Cell Fabric Tangled
Health Lab

Research points to potential new treatment for aggressive prostate cancer subtype

In two separate papers, U-M researchers describe how a gene alteration drives prostate cancer and a potential degrader that stops it
Health Lab

Researchers Pinpoint New Subtype of Prostate Cancer

Tumors with alterations in the CDK12 gene were more responsive to immunotherapy, suggesting a precision medicine approach.

Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Subscribe

Featured News & Stories

Mother sits on a couch with a laptop on her lap while an elementary school age boy sits next to her playing on a tablet device.
Health Lab

New questionnaire aims to improve understanding of demand avoidance in children, teens

Pathological demand avoidance is a pattern of intense distress and avoidance of demands in children. A new questionnaire from University of Michigan researchers creates a structured way to assess these behaviors.
Blue round cells in three pictures showing how they change under stress.
Health Lab

Timing is of the essence for RNA during stress

Key determiners of which RNA can be read to make proteins is time. Previous thinking was that a cell under threat would quickly make these RNAs in the nucleus and immediately push them into the cytoplasm.
Blue and yellow illustration of DNA helix
Health Lab

New anti-cancer strategy shows promise in preclinical studies

New cancer therapeutic strategy rewires protein interactions to improve efficacy and reduce potential side effects.
Closeup of newborn baby, whose head is held by a blue medical gloved hand. Blue gloved hand also holds a stethoscope to baby's chest.
Health Lab

More babies with hypoplastic left heart syndrome surviving critical period between surgeries

Collaborative effort helped sustain improvements in survival for babies born with hypoplastic left heart syndrome (HLHS), a serious congenital heart condition that requires multiple surgeries.
Rachel Upjohn Building groundbreaking ceremony
News Release

How U-M helped bring depression out of the darkness

The history of the founding of the Eisenberg Family Depression Center at the University of Michigan, the nation's first center focused on research, community outreach and stigma reduction in depression and bipolar disorder.
Group of men smiling in a field
News Release

How have diagnostic and treatment decisions for prostate cancer changed in recent years?

An analysis of United States data reveals a broad shift away from overtreatment of low-risk prostate cancer. The analysis by University of Michigan Rogel Cancer Center researchers, indicates a shift toward surveillance in response to concerns of overdiagnosis and overtreatment that have hindered screening in the recent past.